D.R. AKBEROVA

Kazan State Medical University, 49 Butlerov St., Kazan, Russian Federation, 420012

Akberova D.R. — postgraduate student of the Department of Hospital Therapy with a course of Endocrinology, tel. +7-927-411-57-11, e-mail: dile4ek@mail.ru

The liver has a unique vascular system within the gastrointestinal tract, as the majority of the liver’s blood supply comes from the intestine through the portal vein. When the intestinal barrier function is disrupted, an increase in intestinal permeability leads to the translocation of intestine-derived bacterial products such as lipopolysaccharide (LPS) and unmethylated CpG to the liver via the portal vein. These gut-derived bacterial products stimulate innate immune receptors, namely Toll-like receptors (TLRs), in the liver. TLRs are expressed on Kupffer cells, endothelial cells, dendritic cells, biliary epithelial cells, hepatic stellate cells, and hepatocytes. TLRs activate these cells to contribute to acute and chronic liver diseases. At different stages of chronic parenchymal disease of the intestine, especially in the stage of cirrhosis of the liver, increased intestinal permeability, which may aggravate the course of complications such as spontaneous bacterial peritonitis, hepatic encephalopathy, bleeding from varicose veins of the esophagus. Assessment of the severity of the condition, correction of treatment, prevention of complications can be diagnosed by a change in intestinal permeability.

Key words: chronic liver disease, intestinal permeability.

REFERENCES

1. Cesaro C., Tiso A., Del Prete A. et al. Gut microbiota and probiotics in chronic liver diseases. Dig Liver Dis, 2011, Jun, vol. 43(6), pp. 431-8. doi: 10.1016/j.dld.2010.10.015. Epub 2010, Dec 16.
2. Ekihiro Seki and Bernd Schnabl. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol, 2012, Feb 1, vol. 590(Pt 3), pp. 447-458. Published online, 2011, Nov 28. doi: 10.1113/jphysiol.2011.219691.
3. Seo Y.S., Shab V.H. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension. Clin. Mol. Hepatol, 2012, vol. 18(4), pp. 337-346.
4. Miele L., Marrone G., Lauritano C. et al. Gut-liver axis and microbiota in NAFLD: insight pathophysiology for novel therapeutic target. Curr Pharm Des, 2013, vol. 19(29), pp. 5314-5324.
5. Gyongyi Szabo, Shashi Bala, Jan Petrasek et al. Gut-Liver Axis and Sensing Microbes. Dig Dis, 2011, Apr, vol. 28(6), pp. 737-744.
6. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W.Z., Strowig T. et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature, 2012, vol. 482, pp. 179-185.
7. Schnabl B., Brenner D.A. Interactions between the intestinal microbiome and liver diseases. Gastroenterology, 2014, May, vol. 146(6), pp. 1513-24. doi: 10.1053/j.gastro.2014.01.020. Epub 2014, Jan 15.
8. Yajima S., Morisaki H., Serita R. et al. Tumor necrosis factor-alpha mediates hyperglycemiaaugmented gut barrier dysfunction in endotoxemia. Crit Care Med, 2009, vol. 37, pp. 1024-1030.
9. Isabel Gómez-Hurtado, José Such, Yolanda Sanz, and Rubén Francés. Gut microbiota-related complications in cirrhosis. World J Gastroenterol, 2014, Nov 14, vol. 20(42), pp. 15624-15631. Published online 2014 Nov 14. doi: 10.3748/wjg.v20.i42.15624.
10. Masami Minemura and Yukihiro Shimizu. Gut microbiota and liver diseases. World J Gastroenterol, 2015, Feb 14, vol. 21(6), pp. 1691-1702. Published online, 2015, Feb 14. doi: 10.3748/wjg.v21.i6.1691.
11. Garcia-Tsao G., Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol, 2004, Apr, vol. 18(2), pp. 353-72.